HC Wainwright 维持 Sangamo Therapeutics 的“买入”评级，该公司的法布里病疗法 ST-920 有望通过更新的研究计划和欧洲药品管理局优先药物资格获得批准。 HC Wainwright maintains "buy" rating for Sangamo Therapeutics, whose Fabry disease therapy ST-920 sees potential approval with updated study plans and European Medicines Agency priority medicines eligibility.

HC Wainwright 重申了对 Sangamo Therapeutics 的“买入”评级，目标价为 3.00 美元。 HC Wainwright reiterated its "buy" rating for Sangamo Therapeutics, with a price target of $3.00. 这表明潜在的上涨空间为 284.47%。 This suggests a potential upside of 284.47%. Sangamo Therapeutics 的法布里病疗法 ST-920 更新后，其股价上涨 37%。 Sangamo Therapeutics stock increased 37% on updates for its Fabry disease therapy, ST-920. FDA 表示，对最多 25 名患者进行的研究结合确证证据可能足以批准 ST-920。 The FDA has advised that a study of up to 25 patients in combination with confirmatory evidence may be sufficient for approval of ST-920. 欧洲药品管理局已授予该产品优先药品资格，包括加强监管支持和科学指导。 The European Medicines Agency has granted priority medicines eligibility to the product, including enhanced regulatory support and scientific guidance.